Nuveen LLC Invests $2.05 Million in Harrow, Inc. $HROW

Nuveen LLC acquired a new stake in shares of Harrow, Inc. (NASDAQ:HROW) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 76,904 shares of the company’s stock, valued at approximately $2,046,000. Nuveen LLC owned approximately 0.21% of Harrow as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Harrow in the 4th quarter worth approximately $25,000. Tower Research Capital LLC TRC boosted its stake in Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock valued at $55,000 after purchasing an additional 1,462 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Harrow during the 4th quarter valued at $78,000. Rafferty Asset Management LLC bought a new stake in shares of Harrow in the 4th quarter worth $270,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Harrow in the fourth quarter valued at $290,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Stock Performance

Shares of Harrow stock opened at $39.00 on Friday. Harrow, Inc. has a 12 month low of $20.85 and a 12 month high of $59.23. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. The stock has a market cap of $1.44 billion, a PE ratio of -156.00 and a beta of 0.41. The business has a fifty day simple moving average of $34.67 and a 200-day simple moving average of $29.41.

Harrow (NASDAQ:HROW) last issued its earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.23. The company had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Cantor Fitzgerald began coverage on shares of Harrow in a report on Friday, July 11th. They issued an “overweight” rating and a $76.00 price target for the company. Zacks Research upgraded shares of Harrow from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. BTIG Research upped their price target on Harrow from $62.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, August 14th. HC Wainwright raised their price objective on Harrow from $60.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, August 13th. Finally, William Blair initiated coverage on Harrow in a research report on Tuesday, June 10th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. According to data from MarketBeat.com, Harrow currently has an average rating of “Buy” and a consensus price target of $64.67.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.